Navigation Links
New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
Date:6/7/2008

Results Presented at the ADA's Annual Scientific Sessions

SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the results of the dose-finding study for its new injectable diabetes compound AVE0010, a GLP-1 agonist, were presented at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions meeting in San Francisco, California.

The study found that AVE0010 was well tolerated and significantly improved glycemic control versus placebo in type 2 diabetes patients inadequately controlled with metformin alone. The once daily regimen demonstrated a clear dose response with a similar HbA1c reduction to twice daily regimen. AVE0010 was also found to be associated with weight loss and reductions in postprandial glucose.

"The results of the once daily AVE0010 regimen are very promising and this new GLP-1 agonist has a potential to become an important addition to the treatment armamentarium for type 2 diabetes," said Robert Ratner, from the MedStar Research Institute Washington DC, Principal Investigator of the dose-finding study.

About the Study

The dose-finding study involved 542 type 2 diabetes patients inadequately controlled on metformin monotherapy (1.6-1.9 g/day). In this double-blind study, patients were randomized to receive for 13 weeks, either AVE0010 subcutaneously at the doses of 5, 10, 20 and 30 micron(g) once daily or twice daily, or placebo. The primary endpoint was change in HbA1c from baseline. Secondary endpoints included weight change and 2-hour post-prandial plasma glucose (PPG).

Baseline characteristics were similar among groups in terms of mean age (56 +/-9 years), diabetes duration (6.6 +/-5 years), HbA1c (7.5 +/-0.6%) and Body Mass Index (31.9 +/-4 kg/m2). Despite mildly elevated baseline HbA1c, the results of the study demonstrated a highly statistically significant dose response with a net decrease in mean HbA1c from baseline subtracted from placebo f
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
2. DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
3. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
4. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
5. International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India
6. Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
7. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
8. Continued Funding to Help Advance Exciting Moment in Diabetes Research
9. CureDMs Diabetes Therapy Achieves Major Development Milestone
10. Drug Combo Could Lower Diabetes Complications and Costs
11. Discovery Leads to Earlier Diagnosis of Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 BioLineRx (NASDAQ: ... dedicated to identifying, in-licensing and developing promising therapeutic ... underwritten public offering of American Depositary Shares ("ADSs"), ... All of the ADSs in the offering are ... JMP Securities is acting as sole book-running manager ...
(Date:3/5/2015)... Deutschland, 5. März 2015  Die amerikanische ... deutsche biopharmazeutische Unternehmen CureVac geben heute bekannt, ... Millionen US-Dollar) in CureVac investiert. CureVac ist ... Messenger-RNA (mRNA). Auf Basis dieses Moleküls entwickelt ... Krankheiten und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... quarter ended January 31, 2015 on Thursday, March 12 before ... the results at 11:00 AM ET. To ... to 10 minutes before the beginning of the call. If ... call will be available from Thursday, March 12, 2015 through ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... BEIJING , July 12 ... "Company") (NYSE: CCM ), the,operator of the largest ... today announced that effective as of July 1, 2010 ... for the operation of Chang,An,Hospital,s cancer treatment facilities by acquiring ...
... weeks beginning July 12 , ecoSTORE USA ,s elite team of Ecovisors will give ... select Duane Reade drug stores in New York City .  Ecovisors will also ... Nasty Ch e mic a l s™ ... , , ecoSTORE ...
Cached Medicine Technology:Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 2Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 3Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 4Ecovisors to Advise Duane Reade Shoppers 2Ecovisors to Advise Duane Reade Shoppers 3
(Date:3/6/2015)... La (PRWEB) March 06, 2015 Many ... function despite medical therapy. If you (or someone you ... to knee osteoarthritis, you may be interested in the ... Covington Orthopedic announced today that he is one of ... Cytori Therapeutics to begin enrolling subjects as part of ...
(Date:3/6/2015)... 06, 2015 Magellan Rx Management’s 2014 ... source for key trends and statistics on one of ... Executives from Magellan Rx Management will discuss key findings ... Your Hidden Specialty Drug Spend,” a complimentary March 19 ... , Specialty drug spend makes up more than a ...
(Date:3/6/2015)... March 06, 2015 Utilizing the latest ... rapidly reach their ideal weight has enabled Diet Doc ... to their already impressive collection of fat loss enhancement ... clients special promotions and savings to help people throughout ... This promotion is especially appealing to new clients ...
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 Yisrayl ... in Abilene, Texas, has released a new publication explaining ... working. , The article titled “Microorganisms Do ... document explaining how tiny microorganisms were created and designed ... is aware of some of the functions of these ...
(Date:3/6/2015)... March 06, 2015 You Wealth ... created a unique ‘energy’ experiment to determine if ... , After quick ‘5 -7 minute’ remote ... 150+ countries reported their life improving - often ... positive results. , According to research, respondents saw ...
Breaking Medicine News(10 mins):Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2
... on Certain Products Expanded to Retail LevelST. LOUIS, Feb. 3 ... KVa ; KVb), is issuing a voluntary ... on certain products. The recall on the products listed ... is now being expanded to the retail level. The ...
... for Improving Cancer Care Access, Efficiency and Quality; ... NetworkWASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- The ... one of the nation,s largest cancer treatment and ... adopted its Principles for Reforming Cancer Care, designed ...
... 2009) Green tea products have become regarded as ... of its benefit against a variety of diseases, including ... green tea may counteract the anticancer effects of one ... be contraindicated for patients taking this medicine to ensure its ...
... to popular assumptions about the health benefits of green ... have found that the widely used supplement renders a ... cell lymphoma completely ineffective in treating cancer. , ... tea extract (GTE) called EGCG destroys any anticancer activity ...
... 3 VirtualScopics, Inc.,(Nasdaq: VSCP ), a ... that Mr. Jeff Markin, the company,s chief executive,officer, will ... Annual,BIO CEO & Investor Conference at the Waldorf Astoria ... Tuesday, February 10, 2009 at 3:45pm EST. , ...
... prescribed physical activity, survey finds, , , TUESDAY, Feb. 3 (HealthDay ... with and alleviate chronic neck and back pain, a new ... as often as they should. , Less than half ... had seen a physician, chiropractor or physical therapist in the ...
Cached Medicine News:Health News:ETHEX Corporation Issues Voluntary Nationwide Recall 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:USC study finds that green tea blocks benefits of cancer drug 2Health News:VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference 2Health News:Are We Exercising Pain Away? Not So Much. 2
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
... Amsco 3085 SP Surgical Table provides state-of-the-art ... now be networked with the HERMES Control ... Stryker Endoscopy) to allow the surgeon direct ... surgeon uses either simple voice commands or ...
... The ASC 2000 is ... care table, meeting good manufacturing ... regulatory requirements. It provides electro-hydraulic ... accessories for all ambulatory surgical ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: